Neonatal lupus syndrome occurs in infants within the first few months of life and is a transient phenomena. The most common clinical manifestations are erythema annulare centrifugum and congenital heart block. Other associated manifestations include lymphadenopathy, hepatosplenomegaly, and haematological abnormalities consisting of leucopenia, haemolytic anaemia, or thrombocytopenia' -13 The aetiology of the syndrome is unknown. It occurs in infants of mothers with symptomatic connective tissue disease and in infants of asymptomatic mothers with or without connective tissue disease. The SS-A (Ro) antibody has been found in infants with the neonatal lupus syndrome and it has been suggested that transplacental transfer of this antibody is a possible cause.
This study was undertaken to determine the incidence of detectable concentrations of SS-A antibodies in normal mothers and their newborn infants and the predictive value of this measurement for the development of the neonatal lupus syndrome. 
Patients and methods

Blood
Results
Four maternal (1.3%) and four cord (1.3%) samples contained the SS-A antibody. Of these, three maternal and three infant samples belonged to matched mother-infant pairs. The other two positive sera were from one mother with an infant negative for SS-A antibodies and from one infant with a negative mother.
On review of hospital records of the isolated, unmatched positive pairs no evidence of manifestations of connective tissue disease or neonatal lupus syndrome was found in mother and infant respectively. Follow up on these patients was not available. The three SS-A positive mothers, who each delivered one infant also positive for SS-A anti-73 (Table 1) .
Antinuclear antibody testing performed on all SS-A antibody positive mother-infant pairs showed one pair with both negative, one pair in which the mother was negative and the infant was antinuclear antibody positive (1/40 homogeneous) and one pair in which both were antinuclear antibody positive (1/40 homogeneous).
Of the 300 maternal samples tested, only one was positive for SS-B antibodies. There were no SS-B antibody positive infants in the 300 infant samples tested.
Discussion
Neonatal lupus syndrome usually develops between birth and three months of age. Usually, the presentation is characterised by cutaneous Congenital heart block may occur in conjunction with other manifestations of the neonatal lupus syndrome or as an isolated finding.5-7 Similarly, studies have linked the association of the SS-A antibody to congenital heart block in infants with the syndrome.'2 3 SS-A antibody has recently been detected in 83% of mothers of infants with isolated congenital heart block.'3 In the same study, the antibody was present in seven of eight infants with isolated congenital heart block when their serum was tested before three months of age.
A previous study of 50 normal mother-infant pairs found no positive individuals for the SS-A antibody.'3 Weston et al" likewise studied 71 infants from birth to five months of age, of whom 45 were healthy and the others had various reactive erythemas. All 71 of their subjects were negative for SS-A and SS-B antibodies (Table 2 ).
In our study 300 randomly selected mother-infant pairs were tested for SS-A and SS-B antibodies.
Three (1%) of the 300 mother-infant pairs were positive for SS-A antibody but we found no evidence of autoimmune disease or neonatal lupus syndrome in the mothers or infants respectively at the time of birth. Further, no disease activity was ascertained in the two mother-infant pairs available for follow up two and a half months after birth.
The presence of antibody in pairs may represent some antibody cross reactivity with the SS-A antigen, which is also transplacentally passed to the infant. If, however, it in fact represents true SS-A antibody positivity, which may occur in mothers who are asymptomatic for connective tissue disease, then one must either question the aetiological nature of the antibody in producing the neonatal lupus syndrome or assume that an additional, unknown factor determines susceptability or expression. Some significant titre of antibody may be necessary for disease expression and further prospective analysis using data on antibody titre should be performed. Certainly, more studies are needed to evaluate the efficacy of random maternal screening for the presence of SS-A antibodies. Perhaps measurements of simultaneous serial complement components, especially C2, would be useful in patients positive for the SS-A antibody. Our study suggests that any predictive nature of SS-A antibody is doubtful, and SS-A antibody testing would appear not to be cost effective as a mass screening procedure in the detection of infants with the potential to develop neonatal lupus syndrome.
